63 patients in trial but only 35 are ALK+, NSCLC, and treated at 200 to 250 mg daily.
Of those, 8 were ALK inhibitor naive, 7 (88%) had an objective response. 19 patients had received Crizotinib but not another ALK inhibitor, 16 ((84%) had demonstrated reductions in tumor size (unclear how many qualified as partial responses). That leaves 8 patients who presumably were treated with an ALK inhibitor other than or in addition to Crizotinib. No results were in the article for this last group. Responses have lasted as long as 30 months.
In patients with brain mets 63% (5 of 8) had some reduction in size.